Media and Podcasts | About Perimeter | Schedule a Meeting
This content is intended for an investor audience and not for healthcare professionals.
Key to a successful cancer surgery is getting clean margins so surgeons don’t have to make the dreaded call to their patients: “We didn’t get it all.”
Clean margins means there’s a healthy rim of tissue around the excised cancerous tumor so there’s no cancer left behind that could recur or spread. When clean margins are achieved, the chances of local recurrence are significantly lower and this is considered a successful surgery.4
Surgeons will do everything they can to achieve clean margins but they cannot detect remaining cancer cells by sight or touch.
Traditional imaging used in the operating room, such as X-ray, does not have the resolution to detect microscopic cancer cells, and Pathology must be used to confirm clean margins, which takes up to 10 days.
The effects of repeat surgeries or re-excisions are devastating.
Let’s take the example of Janeye, a breast cancer patient. She gets the call that she needs a repeat surgery. To avoid any further issues, she chooses to have a mastectomy, linked to a 30% increased risk of complications.13
With this, her risk of complications and the overall severity of the surgery increases, moving the finish line for recovery even farther out. On top of that, her body is further altered and the emotional toll of it all is devastating for Janeye and her family.
*Reoperation data from commercial insurance cohort
Perimeter’s proprietary Optical Coherence Tomography (OCT) technology, available now, provides high-definition, 3D images of margins in the operating room, enabling surgeons to see difficult-to-detect disease when it matters most.
By gaining clarity on margins status in the OR rather than waiting days for pathology results, surgeons can act in the moment with confidence and potentially avoid the dreaded phone call.
**The S-Series OCT has a general indication and has not been evaluated by FDA for specific uses. More information here.
Following a successful clinical trial in which the primary endpoint was met (statistically significant reduction in patients with residual cancer during lumpectomy with adjuvant use of B-Series), we have submitted our next-generation product, B-Series with AI, to the FDA — on track to become the first FDA-approved AI-enabled device in the breast surgical oncology market by early 2026.
***Perimeter B-Series OCT is not available for sale in the United States. CAUTION – Investigational device. Limited by U.S. law to investigational use.
This content is intended for an investor audience and not for healthcare professionals.
FOX 26’s Melissa Wilson spoke with Dr. Alastair Thompson, lead Primary Principal Investigator of Perimeter’s clinical trial and Section Chief of Breast Surgery and Professor at Baylor College of Medicine, to hear more details about the trial and exciting advancements in the fight against breast cancer.
Perimeter CEO Adrian Mendes joins Tom Salemi on an episode of the DeviceTalks podcast to discuss his path into medtech and how Perimeter hopes to use OCT and AI to boost surgeon confidence and patient peace of mind.
Perimeter CEO Adrian Mendes speaks with Karen Jagoda about how OCT gives surgeons high-definition real-time visibility into tumor margins.
Cancer is a global challenge, and we envision a world where patients no longer experience the costly emotional and physical trauma of being called back for a second surgery due to cancer left behind.
Perimeter Medical Imaging AI is a medical technology company seeking to revolutionize medical imaging with groundbreaking technologies that address unmet needs and are widely recognized as the new standard of care.
Perimeter seeks to harness the power of big data, artificial intelligence, and machine learning technology to further its mission of advancing the standard of care, improving patient outcomes, and reducing healthcare costs.
Fill out the form to set up a meeting with Adrian Mendes, CEO, and Sara Brien, CFO.
Adrian Mendes, CEO
Sara Brien, CFO